Federal Circuit Confirms Patent Eligibility of Gene Therapy Patent in Regenexbio Inc. v. Sarepta Therapeutics
Key Takeaway: Genetically engineered cultured host cells containing recombinant nucleic acids useful for gene therapy are patent-eligible for being markedly different from anything occurring in nature. In REGENXBIO Inc. v....
Jeremiah Helm Shares Post-Argument Insights on Supreme Court “Skinny Label” Patent Infringement Case, Hikma v. Amarin
Following April 29 oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the closely watched Supreme Court case on whether a generic drug manufacturer can be held liable...
SMEDs Are Working: What the USPTO’s Updated § 101 Patent Eligibility Guidance Means for Innovators
Key Takeaway: The U.S. Patent and Trademark Office’s April 30, 2026 memorandum encourages patent applicants to submit separate declarations supporting “subject matter eligibility” (SMEDs) in response to § 101 rejections....
Subscribe for News and Updates